Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CE-Mark for self-test for VISITECT® COVID-19 test

3 Feb 2022 07:00

RNS Number : 5386A
Omega Diagnostics Group PLC
03 February 2022
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

CE-Mark for self-test for VISITECT® COVID-19 antigen test

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products announces that it has successfully CE marked its VISITECT® COVID-19 antigen test for self-test use.

 

The test will provide consumers with an accurate rapid test for the detection of the nucleoprotein of the SARS-CoV-2 virus in nasal swabs only. The VISITECT® COVID-19 antigen test has excellent performance characteristics following independent multi-centre validations, with sensitivity of 93.2% based on 103 samples with cycle threshold (Ct) values

 

The Company remains in discussions with commercial partners about how best to service the European market and other territories that recognise the CE mark. Omega's commercial offering will be via B2B partners and distributors, and not through a direct-to-consumer strategy.

 

The CE Mark certificate is conditional upon the submission of additional data and follow-up reports by 31 March 2022 and Omega is working closely with its external study centres to ensure this deadline is met.

 

Omega remain in the review process under CTDA regulations, which were introduced on 1 November 2021. Further field study data has been recently requested. Omega is seeking this information from external parties but this may not be available prior to the current extended deadline for submission of 10 February 2022.

 

Jag Grewal, CEO of Omega, commented: "We are delighted to have reached this milestone, achieving CE Mark for our VISITECT® COVID-19 antigen test for the home-use market. It is frustrating that our test is still awaiting approval under CTDA regulations for sale of the professional-use test in the UK. We will now look to begin the process of filing for approval to sell our home-use product in the UK. In the meantime, we look forward to working with prospective partners to determine the best route to market."

 

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Contacts: 

 

Omega Diagnostics Group PLC

www.omegadiagnostics.com

Jag Grewal, Chief Executive Officer

via Walbrook PR

Chris Lea, Chief Financial Officer

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash / Edward Whiley (Corporate Finance)

Alice Lane / Charlotte Sutcliffe (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / 07584 391 303

Sam Allen

Mob: 07502 558 258

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEADAAEASAEAA
Date   Source Headline
6th Sep 20237:00 amRNSAGM Statement
1st Sep 202310:29 amRNSUpdate on proposed Share Reorganisation
31st Aug 20237:00 amRNSProposed Share Reorganisation Timetable
22nd Aug 20237:00 amRNSDirectorate Change
17th Aug 20237:00 amRNSBoard Appointment
15th Aug 20231:45 pmRNSDirector/PDMR Shareholding
14th Aug 20237:00 amRNSPosting of Annual Report and confirmation of AGM
3rd Aug 20237:00 amRNSFinal Results
27th Jul 20237:00 amRNSNotice of Results
26th Jul 20232:10 pmRNSHolding(s) in Company
6th Jun 202311:19 amRNSHolding(s) in Company
5th Jun 20234:51 pmRNSHolding(s) in Company
2nd Jun 20232:45 pmRNSHolding(s) in Company
22nd May 20235:33 pmRNSHolding(s) in Company
10th May 20237:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
9th May 20233:42 pmRNSDirector/PDMR Shareholding
21st Apr 20239:48 amRNSHolding(s) in Company
19th Apr 20239:31 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSTrading Update
22nd Mar 20235:57 pmRNSBlock Listing Six Monthly Return
22nd Mar 20233:00 pmRNSHolding(s) in Company
6th Mar 20232:31 pmRNSHolding(s) in Company
27th Jan 20233:03 pmRNSHolding(s) in Company
27th Jan 20239:36 amRNSDirector/PDMR Shareholding
18th Jan 20237:00 amRNSTrading update
16th Jan 202310:56 amRNSHolding(s) in Company
6th Jan 20237:00 amRNSUS expansion update
3rd Jan 202312:34 pmRNSHolding(s) in Company
13th Dec 20224:40 pmRNSSecond Price Monitoring Extn
13th Dec 20224:35 pmRNSPrice Monitoring Extension
13th Dec 202212:01 pmRNSHolding(s) in Company
30th Nov 20229:35 amRNSHolding(s) in Company
25th Nov 20227:00 amRNSReceipt of deferred consideration
24th Nov 20227:00 amRNSHalf-year Report
23rd Nov 20224:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20224:36 pmRNSPrice Monitoring Extension
23rd Nov 20222:05 pmRNSSecond Price Monitoring Extn
23rd Nov 20222:00 pmRNSPrice Monitoring Extension
18th Nov 202212:09 pmRNSHolding(s) in Company
16th Nov 20222:06 pmRNSSecond Price Monitoring Extn
16th Nov 20222:00 pmRNSPrice Monitoring Extension
15th Nov 20227:00 amRNSConfirmation of Results and Investor Presentation
14th Nov 20227:00 amRNSPartnership agreement with Software Provider
8th Nov 20229:04 amRNSLaunch of new all-employee share incentive plan
26th Oct 20222:50 pmRNSResult of AGM
26th Oct 20227:00 amRNSAGM Statement and Notice of Results
11th Oct 20227:00 amRNSScientific Director to present at FIDHC
5th Oct 20227:00 amRNSPositive WHO data received for VISITECT® CD4 test
27th Sep 20227:00 amRNSPosting of Annual Report and confirmation of AGM
20th Sep 202212:05 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.